Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival (Q38279587)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 October 2014

Language	Label	Description	Also known as
English	Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival	scientific article published on 24 October 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1 reference

Europe PubMed Central

Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

J Tate Thigpen

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

language of work or name

0 references

publication date

24 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

136

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

121-129

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Ten-year relative survival for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Measures of response: RECIST, WHO, and new alternatives

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

PFS: the endpoint we love and love to hate

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Overview: progression-free survival as an endpoint in clinical trials with solid tumors

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

First-line therapy in ovarian cancer trials.

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2014.10.010

7 January 2021

Identifiers

10.1016/J.YGYNO.2014.10.010

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38279587&oldid=1751745859"